Hepatitis C Calculator: Global Cost-Effectiveness Analysis of Treatment

2018

Globally, an estimated 71 million people are living with hepatitis C virus. Newly introduced direct-acting antivirals (DAAs) are highly effective in the treatment of hepatitis C and well tolerated, but are much more expensive compared to conventional treatments. The Hep C Calculator is an interactive web-based tool using Shiny from R studio, which allows the user to evaluate the cost-effectiveness of DAAs for the global treatment of Hepatitis C infection. 

The tool is based on a validated Markov cohort model called the “Markov-based Analyses of Treatments for Chronic Hepatitis C” or “MATCH”. This model simulates multi-stage disease progression of a hepatitis C-infected population in 28 countries that are considered priority countries by the World Health Organization, including several countries in Asia, South America, sub-Saharan Africa, North Africa, and Eastern Europe.

The tool allows users to explore the impact of several input parameters on cost-effectiveness results including the specific country, prices of DAAs and laboratory tests, cost of management of disease stages including sequelae (e.g., cirrhosis and liver cancer), mean age and the relative distribution of fibrosis stages for a given population. Besides cost-effectiveness outcomes, the tool also presents the change in disease burden over time in terms of cumulative incidence of liver-related deaths, hepatocellular carcinoma, and decompensated cirrhosis. The tool is developed by the MGH Institute for Technology Assessment in collaboration with WHO.

 

Source:

Hep C Calculator: Global Cost-Effectiveness Analysis of Hepatitis C Treatment. MGH Institute for Technology Assessment 2018. https://www.hepccalculator.org